It has been suggested that BST-2 downmodulation serves to protect infected cells from antibody-dependent cellular cytotoxicity (ADCC) by minimizing cell surface publicity of viral antigen (3436). TM subunit was adequate to confer Vpu-like activity to an inactive Env variant. Surprisingly, however , absence of Vpu-like activity was not correlated with absence of BST-2 interaction. Taken with each other, our data Pyrindamycin B suggest that maintaining the ability to antagonize BST-2 is of functional relevance not only to HIV-1 but also to HIV-2 as well. Our data show that as with Vpu, binding of HIV-2 Env to BST-2 is important but not adequate for antagonism. Finally, because observed previously, the Vpu-like activity in HIV-2 Env can be managed by single-residue changes in the TM subunit. IMPORTANCELentiviruses such as HIV-1 and HIV-2 encode accessory proteins whose function is to overcome web host restriction mechanisms. Vpu is a well-studied HIV-1 accessory protein that enhances virus release by antagonizing the web host restriction element BST-2. HIV-2 does not encode avpugene. Instead, the HIV-2 Env glycoprotein was discovered to antagonize BST-2 in some isolates. Here, we cloned multiple Env sequences from 7 HIV-2-infected patients and found that about half were able to antagonize BST-2. Importantly, most HIV-2 patients harbored a mixed population of viruses that contains or missing the ability to antagonize BST-2. In fact , in evaluating Env sequences from one patient combined with site-directed mutagenesis, we were able to bring back BST-2 antagonism to an inactive Env protein by a single-amino-acid change. Our data suggest that targeting BST-2 by HIV-2 Env is a dynamic process that can be regulated by simple changes in the Env sequence. == INTRODUCTION == Human immunodeficiency virus type 1 (HIV-1) and type 2 (HIV-2) infections are well defined as viral zoonoses. Phylogenetic analysis shows that HIV-1 is closely related to simian immunodeficiency virus (SIV) from chimpanzees (SIVcpz), and HIV-2 is closely related to SIV from sooty mangabeys (SIVsm) (1). At least nine lineages of HIV-2 have been recognized, referred to as HIV-2 groups A through I. However , only groups A and W are known to cause human being epidemics. In fact , group A viruses take into account the vast majority of HIV-2 infections globally, which are concentrated mainly in West Africa, Europe, and some Asian countries (13). Like all primate retroviruses, HIV-2 encodes three structural proteins (Gag, Pol, and Env) and a set of accessory proteins (Vif, Vpx, Vpr, and Nef). Most, if not all, from the accessory proteins serve to antagonize host restriction factors, which are part of the host’s innate immune system and are regarded as a first line of defense against viruses. Overall, the genomes of HIV-1 and HIV-2 are very similar. Two significant differences are (i) the presence of avpugene in HIV-1 which is absent from HIV-2 and (ii) the absence of avpxgene in HIV-1 which is present in HIV-2. Vpu targets bone marrow stromal antigen 2 (BST-2) and induces degradation of CD4, while Vpx induces degradation of sterile alpha motif and HD domain-containing protein 1 (SAMHD1) (for a review, see reference4). There is no known functional homolog to Vpx in HIV-1 to target SAMHD1, and while Nef is well known to downregulate CD4 from the cell surface (5), the ability to induce proteasomal degradation of CD4 is limited to viruses expressing Vpu (6, 7). Thus, the Vpu and Pyrindamycin B Vpx proteins are not functional homologs. On the other hand, a chance to enhance computer virus release by antagonizing BST-2 is not limited to Vpu-encoding viruses. In fact , in HIV-2, antagonizing BST-2 is a functional property from the Env glycoprotein (8, 9), while in SIV this function is executed by the Nef protein (1013). Intended for the remainder Tlr4 of this work, we refer to the ability of HIV-2 to enhance computer virus release because Vpu-like activity. BST-2, also known as tetherin or CD317, is a 30- to 36-kDa type II transmembrane protein that inhibits the release of retrovirus particles by physically tethering virions to the cell surface (14, 15). The exact mechanism of how Vpu antagonizes BST-2 is still Pyrindamycin B unclear. However , it is thought to involve Pyrindamycin B a process that interferes with the resupply of newly synthesized BST-2 from the endoplasmic reticulum (ER) to the cell surface (reviewed in reference4). Similar to HIV-1 Vpu, the ability of HIV-2 Env.
